https://www.selleckchem.com/products/kpt-9274.html
ers. On study completion, and following a predetermined embargo period, CPSS data are planned to be made accessible for analysis to facilitate further research into the determinants of AD pathology, onset of symptomatology and progression. The CHARIOTPRO SubStudy is registered with clinicaltrials.gov (NCT02114372). Notices of protocol modifications will be made available through this trial registry. The CHARIOTPRO SubStudy is registered with clinicaltrials.gov (NCT02114372). Notices of protocol modifications will be made available thro
Like
Comment
Share
